Ensemble Modeling of Cancer Metabolism

The metabolic behavior of cancer cells is adapted to meet their proliferative needs, with notable changes such as enhanced lactate secretion and glucose uptake rates. In this work, we use the Ensemble Modeling (EM) framework to gain insight and predict potential drug targets for tumor cells. EM generates a set of models which span the space of kinetic parameters that are constrained by thermodynamics. Perturbation data based on known targets are used to screen the entire ensemble of models to obtain a sub-set, which is increasingly predictive. EM allows for incorporation of regulatory information and captures the behavior of enzymatic reactions at the molecular level by representing reactions in the elementary reaction form. In this study, a metabolic network consisting of 58 reactions is considered and accounts for glycolysis, the pentose phosphate pathway, lipid metabolism, amino acid metabolism, and includes allosteric regulation of key enzymes. Experimentally measured intracellular and extracellular metabolite concentrations are used for developing the ensemble of models along with information on established drug targets. The resulting models predicted transaldolase (TALA) and succinyl-CoA ligase (SUCOAS1m) to cause a significant reduction in growth rate when repressed, relative to currently known drug targets. Furthermore, the results suggest that the synergistic repression of transaldolase and glycine hydroxymethyltransferase (GHMT2r) will lead to a threefold decrease in growth rate compared to the repression of single enzyme targets.

[1]  O. Warburg On respiratory impairment in cancer cells. , 1956, Science.

[2]  David M. Kramer,et al.  Biochemistry and Molecular Biology , 1968, Nature.

[3]  C. J. Hedeskov Early effects of phytohaemagglutinin on glucose metabolism of normal human lymphocytes. , 1968, The Biochemical journal.

[4]  H. Morris,et al.  Enzymatic and immunological studies on pyruvate carboxylase in livers and liver tumors. , 1973, Cancer research.

[5]  J. Foker,et al.  Aerobic glycolysis during lymphocyte proliferation , 1976, Nature.

[6]  M. Ookhtens,et al.  Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. , 1984, The American journal of physiology.

[7]  K. Brand Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. , 1985, The Biochemical journal.

[8]  B Crabtree,et al.  The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells , 1985, Bioscience reports.

[9]  P. Coleman,et al.  Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. , 1986, Biochimica et biophysica acta.

[10]  R. Curi,et al.  Metabolism of pyruvate by isolated rat mesenteric lymphocytes, lymphocyte mitochondria and isolated mouse macrophages. , 1988, The Biochemical journal.

[11]  B. Nelson,et al.  Expression of a new set of glycolytic isozymes in activated human peripheral lymphocytes. , 1990, Biochimica et Biophysica Acta.

[12]  D. Leibfritz,et al.  A 13C NMR study on fluxes into the TCA cycle of neuronal and glial tumor cell lines and primary cells. , 1992, Biochimie.

[13]  M R Grever,et al.  The National Cancer Institute: cancer drug discovery and development program. , 1992, Seminars in oncology.

[14]  M. Guppy,et al.  The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. , 1993, European journal of biochemistry.

[15]  J. Portais,et al.  Glucose and glutamine metabolism in C6 glioma cells studied by carbon 13 NMR. , 1996, Biochimie.

[16]  G. Pasternack,et al.  Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. , 1996, Cancer research.

[17]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Palsson,et al.  Toward Metabolic Phenomics: Analysis of Genomic Data Using Flux Balances , 1999, Biotechnology progress.

[19]  C. Thompson,et al.  Akt and Bcl-xL Promote Growth Factor-independent Survival through Distinct Effects on Mitochondrial Physiology* , 2001, The Journal of Biological Chemistry.

[20]  Marta Cascante,et al.  Metabolic profiling of cell growth and death in cancer: applications in drug discovery. , 2002, Drug discovery today.

[21]  C. Chassagnole,et al.  Dynamic modeling of the central carbon metabolism of Escherichia coli. , 2002, Biotechnology and bioengineering.

[22]  P. Hammerman,et al.  Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival , 2003, Molecular and Cellular Biology.

[23]  R. Mahadevan,et al.  The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. , 2003, Metabolic engineering.

[24]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[25]  B. Palsson,et al.  Genome-scale models of microbial cells: evaluating the consequences of constraints , 2004, Nature Reviews Microbiology.

[26]  I. Birol,et al.  Metabolic control analysis under uncertainty: framework development and case studies. , 2004, Biophysical journal.

[27]  C. Thompson,et al.  ATP citrate lyase is an important component of cell growth and transformation , 2005, Oncogene.

[28]  R. Deberardinis,et al.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.

[29]  Daniel E Bauer,et al.  ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.

[30]  O. Fiehn,et al.  Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. , 2006, Cancer research.

[31]  T. Schulz,et al.  Induction of Oxidative Metabolism by Mitochondrial Frataxin Inhibits Cancer Growth , 2006, Journal of Biological Chemistry.

[32]  Sang Yup Lee,et al.  WebCell: a web-based environment for kinetic modeling and dynamic simulation of cellular networks , 2006, Bioinform..

[33]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[34]  T. Powell,et al.  Mammalian target of rapamycin in the human placenta regulates leucine transport and is down‐regulated in restricted fetal growth , 2007, The Journal of physiology.

[35]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[36]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[37]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[38]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[39]  J. Liao,et al.  Ensemble modeling of metabolic networks. , 2008, Biophysical journal.

[40]  Markus J. Herrgård,et al.  Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.

[41]  Matthew D. Jankowski,et al.  Group contribution method for thermodynamic analysis of complex metabolic networks. , 2008, Biophysical journal.

[42]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[43]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[44]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[45]  W. Linehan,et al.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.

[46]  James C Liao,et al.  Ensemble modeling for strain development of L-lysine-producing Escherichia coli. , 2009, Metabolic engineering.

[47]  Yanlei Ma,et al.  Searching for serum tumor markers for colorectal cancer using a 2‐D DIGE approach , 2009, Electrophoresis.

[48]  G. Sprenger,et al.  Transaldolase: from biochemistry to human disease. , 2009, The international journal of biochemistry & cell biology.

[49]  Rachel Cavill,et al.  Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). , 2009, Journal of proteome research.

[50]  M. Tomita,et al.  Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. , 2009, Cancer research.

[51]  Yi Zhou,et al.  Catabolic efficiency of aerobic glycolysis: The Warburg effect revisited , 2010, BMC Systems Biology.

[52]  M. Boulton Cell Culture , 2010, Cell.

[53]  V. Mootha,et al.  Discovery and therapeutic potential of drugs that shift energy metabolism from mitochondrial respiration to glycolysis , 2010, Nature Biotechnology.

[54]  Kidong Park,et al.  Measurement of adherent cell mass and growth , 2010, Proceedings of the National Academy of Sciences.

[55]  J. Liao,et al.  Ensemble modeling of hepatic fatty acid metabolism with a synthetic glyoxylate shunt. , 2010, Biophysical journal.

[56]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[57]  J. Liao,et al.  Reducing the allowable kinetic space by constructing ensemble of dynamic models with the same steady-state flux. , 2011, Metabolic engineering.

[58]  E. Ruppin,et al.  Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.

[59]  Roded Sharan,et al.  Genome-Scale Metabolic Modeling Elucidates the Role of Proliferative Adaptation in Causing the Warburg Effect , 2011, PLoS Comput. Biol..

[60]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.